You are here: Home » News-CM » Companies » News
Business Standard

Jubilant Life Sciences provides update on subsidiary - Jubilant Pharma

Capital Market 

Board of Jubilant Pharma approves of speciality pharma business in US

Jubilant Life Sciences announced that the Board of Jubilant Pharma (JPL), a material wholly owned subsidiary of the Company in Singapore, has approved to negotiate a potential of a specialty pharma business in the United States using only internal accruals, subject to due diligence, satisfactory agreements, etc. and its final approval. The proposed is a niche, profitable speciality pharma business with a strategic fit and is expected to provide competitive edge for JPL's existing business, if it materialises.

Powered by Capital Market - Live News

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Jubilant Life Sciences provides update on subsidiary - Jubilant Pharma

Board of Jubilant Pharma approves acquisition of speciality pharma business in US

Board of Jubilant Pharma approves of speciality pharma business in US

Jubilant Life Sciences announced that the Board of Jubilant Pharma (JPL), a material wholly owned subsidiary of the Company in Singapore, has approved to negotiate a potential of a specialty pharma business in the United States using only internal accruals, subject to due diligence, satisfactory agreements, etc. and its final approval. The proposed is a niche, profitable speciality pharma business with a strategic fit and is expected to provide competitive edge for JPL's existing business, if it materialises.

Powered by Capital Market - Live News

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Jubilant Life Sciences provides update on subsidiary - Jubilant Pharma

Board of Jubilant Pharma approves of speciality pharma business in US

Jubilant Life Sciences announced that the Board of Jubilant Pharma (JPL), a material wholly owned subsidiary of the Company in Singapore, has approved to negotiate a potential of a specialty pharma business in the United States using only internal accruals, subject to due diligence, satisfactory agreements, etc. and its final approval. The proposed is a niche, profitable speciality pharma business with a strategic fit and is expected to provide competitive edge for JPL's existing business, if it materialises.

Powered by Capital Market - Live News

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

image
Business Standard
177 22